

MINUTES  
 AREA DRUG AND THERAPEUTICS COMMITTEE  
 WEDNESDAY 21<sup>st</sup> DECEMBER 2022 @10am  
 Microsoft Teams Meeting

		Action
2022/180	<p>1. <b><u>Apologies for Absence</u></b>            Emma Harris</p> <p><b><u>In Attendance</u></b></p> <p>Mehrdad Malekian (MM) Chair            Gail Richardson (GR)            John Milne (JM) (until item 6)            Carol McGoff (CM)            Stephanie Dundas (SD)            Karen Patterson (KP)            Penny Brankin (PB)            Tyra Smith (TS)            Christine Gilmour (CG)</p>	<p>Victoria Gemmell (VG) Minutes            David Semple (DS)            Mark Kirk (MK)</p>
2022/181	<p>2. <b><u>Declaration of Interest</u></b></p> <p>nil</p>	
2022/182	<p>3. <b><u>Matters arising not covered elsewhere on the agenda</u></b></p> <p>a. <b><u>Ratification of minutes of meeting 16<sup>th</sup> November 2022</u></b></p> <p>Some small changes agreed. To be finally ratified next meeting</p> <p>b. <b><u>Antenatal Gentamicin Chart</u></b></p> <p>Chart agreed.</p> <p>c. <b><u>Osteoporosis Guideline Update</u></b></p> <p>Links to Q-Fracture and FRAX to be added            Approval dates etc. to be added, however content agreed by group.</p> <p>d. <b><u>Asthma treatment</u></b> (Trimbow®)</p> <p>Discussion around who should review patient-amend to “original prescribing team would review”</p>	<p><b>VG</b></p> <p><b>MM</b></p>

	<p>Request for author to communicate this addition widely The group agreed a formulary amendment form may be helpful</p> <p>MM to discuss changes but protocol broadly approved</p> <p><b>e. <u>Dermatology Update</u></b></p> <p>Abrocitinib-Typo in treatment requirements section. Content agreed for all protocols other than minor changes It was agreed that links to vaccination info might be helpful</p> <p>The committee were noted the draft pathways were very helpful and it would be useful to include on guidelines website once finalized. MM to contact author to convert to NHSL guidelines template.</p> <p>Eczema pathway-not clear what over 65's can use-could reword</p> <p>There was discussion about where clinical protocols for new medicines are held and that they are rarely updated or resubmitted. It was agreed it would be helpful if these were hosted somewhere accessible to clinicians. The clinical protocol template may benefit from a refresh with a view to where it will be hosted. The group were asked to consider this with a view to future discussion.</p> <p><b>f. <u>Antimicrobial</u></b></p> <p>AMC abbreviation needs expanded, as they are several groups who use this abbreviation. Content agreed</p> <p><b>g. <u>Ferrous Sulfate SBAR</u></b></p> <p>Some small changes requested, including change of title to cover oral iron preparations. To be circulated widely via normal comms, to be added to guidelines website and included in Prescribing Notes Approval dates to be added To be circulated to nursing and midwives-Cheryl Clark Chief Midwife at UHW would be the contact.</p>	<p><b>MM</b></p> <p><b>MM</b></p> <p><b>All</b></p> <p><b>SD</b></p> <p><b>VG/ MM</b></p>
2022/183	<p><b>4. <u>SMC Advice</u></b></p> <p><b><u>Full Submission</u></b></p> <ul style="list-style-type: none"> <li>• mobocertinib (Exkivity) Takeda UK Ltd SMC2516 <b>Accepted with PAS</b></li> </ul> <p>This was noted and the Scottish Cancer Network will provide</p>	

guidance

**Resubmissions**

• ferric maltol (Feraccru) Norgine Pharmaceuticals Ltd SMC2500 **Not Recommended**  
FOR NOTING

• tepotinib (Tepmetko) Merck Serono Ltd SMC2535 **Accepted with PAS**

This was noted and the Scottish Cancer Network will provide guidance

**Non Submissions**

FOR NOTING

- estetrol / drospirenone (Drovelis®) Gedeon Richter UK Ltd SMC2564
- setmelanotide (Imcivree®) Rhythm Pharmaceuticals SMC2565
- tisagenlecleucel (Kymriah®) Novartis Pharmaceuticals UK Ltd SMC2566

**Amended Advice**

upadacitinib 15mg prolonged-release tablets (Rinvoq®) AbbVie Ltd SMC2495

Minor amendments have been made to the Detailed Advice Document for upadacitinib (Rinvoq®), for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.

This was noted previously and has been referred to Rheumatology

**Outwith remit decisions (based on criterion 14)**

For a trial period, we are advising Boards on outwith remit decisions relating to criterion 14\*, made following a company query. These are provided in the table below.

*\*Criterion 14: The product is a new formulation (or combination) of an established medicine which is either:*

- *An oral formulation of an established generic medicine intended for patients unable to swallow tablets or capsules, or;*
- *An alternative formulation of an established medicine (accepted for use by SMC/HIS or which pre-dates SMC) which costs the same per patient or less*

Product	Formulation	Company	Indication
---------	-------------	---------	------------

	travoprost (Visutrax)	40 mg/mL eye drops solution	VISUfarma UK Ltd	Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma  Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma
	human protein C (Ceprotrin)	SC formulation	Takeda UK Ltd	Prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency
<p>FOR NOTING</p> <p><b><u>Ultra-Orphan</u></b></p> <p>The following medicine <b>did not meet</b> the revised UO definition:</p> <ul style="list-style-type: none"> <li>• belzutifan (Welireg) for the treatment of adult patients with VHL disease who require therapy for VHL-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable</li> <li>• tabellecleucel (Ebvallo) as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate</li> </ul>				
2022/184	5.	<b><u>SMC follow up</u></b>		
FOR NOTING				
2022/185	6.	<b><u>Lanarkshire Formulary</u></b>		
<p>CM presented two proposed amendments to the formulary. The first was to change the preferred brand of enoxaparin from Inhixa to Clexane. The second was the addition of information regarding emergency contraception and the copper intra-uterine device. Both amendments were ratified by the Committee.</p>				
2022/186	7.	<b><u>Clinical Protocols</u></b>		
	(a)	<u>Infliximab</u> (Remsima®) Protocol agreed		

	(b) <b><u>Roxadustat</u></b> To be resubmitted using correct template.	
	(c) <b><u>Utrogestan</u></b> Text should be in black, needs transferred to current template Trade mark to be added, Latin wording to be removed. Issue around reference to unlicensed use To return for final approval	<b>MM</b>
2022/187	8. <b><u>ADTC New Medicines Decisions</u></b>  Bulletin for noting	
2022/188	9. <b><u>Unlicensed Medicines</u></b>  <b><u>Neostigmine &amp; Morphine</u></b>  Request discussed and agreed	
2022/189	10. <b><u>Patient Group Directions</u></b>  (a) <b>Ibuprofen</b> (b) <b>PGDs from the Infertility Service</b>  It was commented that ADTC may not be the most appropriate forum for approval of PGD's. Further discussions to take place offline regarding this.	<b>CG</b>
2022/190	11. <b><u>Medication and Clinical risk in Lanarkshire</u></b> <a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a>  nil	
2022/191	12. <b><u>Regional Cancer Advisory Network</u></b>  nil	
2022/192	13. <b><u>Patient Safety Alerts</u></b>  nil	
2022/193	14. <b><u>Lay member related items</u></b>  nil	

2022/194 15.	<p><b><u>ADTCC Correspondence</u></b></p> <p><b><u>(ADTC) Collaborative</u></b></p> <p>nil</p>	
2022/195 16.	<p><b>Pharmacy &amp; NMAHP Prescribing Governance</b></p> <p>nil</p>	
2022/196 17.	<p><b><u>AOCB</u></b></p> <p>(a) <b><u>Ranolazine:</u></b> This medicine was reviewed by SMC in 2012 and not recommend for use, therefore requests for use have been managed via the PACS-2 process. Ranolazine is now included in NICE guidance, which was last reviewed in Oct 2022; there are no specific safety concerns or monitoring requirements. SMC do not review their guidance and the manufacturer has no intention of re-submitting to SMC. Since 2012 there have been IPTR/PACS-2 requests submitted locally to support cardiology to prescribe this medicine for specific patients. To date all requested have been supported. The committee discussed this medicines and agreed to review the status of this medicine in light of emerging evidence and clinical practice. It was agreed that the medicine is now accepted for use in NHS Lanarkshire and that PACS-2 forms are no longer required. The committee was clear that this did not undermine SMC process.</p> <p>(b) <b><u>VTE prophylaxis in Orthopaedic patients</u></b></p> <p>Question raised with regards to proforma used in orthopaedic wards as this may not be in keeping with approved guidance. Agreed that more information is required in terms of origin of this document and its relation to approved guidance in order to consider need for remedial action to be taken.</p> <p>(c) (i) <b>Antibiotic management of Group A Streptococcus (GAS, <i>Strep. pyogenes</i>) infection in children</b></p> <p>(ii) <b>Group A Strep Guidance</b></p> <p>These were discussed by the group and agreed.</p> <p>(iii) New email for Medicines Guidance Team was highlighted.</p> <p>medsguidance@lanarkshire.scot.nhs.uk</p>	<p><b>CG</b></p> <p><b>KP/ PB</b></p>

2022/197 18.	<b><u>Date of next meeting</u></b> 18 <sup>th</sup> January 2023 @ Microsoft Teams 10am	
--------------	--	--